Portal de investigação
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- D'Amico, F
- Rubin, DT
- Kotze, PG
- Siegmund, B
- Kobayashi, T
- Olivera, PA
- Bossuyt, P
- Pouillon, L
- Louis, E
- Domènech, E
- Ghosh, S
- Danese, S
- Peyrin-Biroulet, L
Unidades de investigação
Abstract
Background Fecal calprotectin (FC) is a non-invasive marker of gut inflammation which is frequently used to guide therapeutic decisions in patients with inflammatory bowel diseases (IBD). Each step of FC measurement can influence the results, leading to misinterpretations and potentially impacting the management of IBD patients. To date, there is high heterogeneity between FC measurements and no current method is universally accepted as a standard. Aims Our aim was to provide clear position statementsabout the pre-analytical and the analytical phases of FC measurement to homogenize FC levels and to minimize variability and risk of misinterpretation through aninternational consensus. Materials & Methods Fourteen physicians with expertise in the field of IBD and FC from 11 countries attended a virtual international consensus meeting on July 17th, 2020. A systematic literature was conducted and the literature evidence was shared and discussedamong the participants. Statements were formulated, discussed, and voted. Statements were considered approved if all participants agreed. Results Nine statements were formulated and approved. Based on the available evidence, quantitative tests should be preferred for measuring FC. Furthermore, FC measurement, if possible, should always be performed with the same method and factors influencing FC levels should be taken into account when interpreting the results. Discussion FC has an increasingly important role in the management of patients with IBD. However, large multicenter studies should be conducted to define the reproducibility and to confirm the diagnostic accuracy of the available FC tests. Conclusion FC concentrations guide clinicians' treatment decisions. Our statements have a relevant impact in daily practice and could be applied in clinical trials to standardize FC measurement.
Dados da publicação
- ISSN/ISSNe:
- 2050-6406, 2050-6414
- Tipo:
- Article
- Páginas:
- 451-460
- DOI:
- 10.1002/ueg2.12069
- Link para outro recurso:
- www.scopus.com
United European Gastroenterology Journal John Wiley & Sons Inc.
Citações Recebidas na Web of Science: 24
Citações Recebidas na Scopus: 52
Documentos
- Não há documentos
Filiações
Keywords
- fecal calprotectin; inflammatory bowel disease; measurement; standardization
Financiamento
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
D'Amico F,Rubin DT,Kotze PG,Magro F,Siegmund B,Kobayashi T,Olivera PA,Bossuyt P,Pouillon L,Louis E,Domènech E,Ghosh S,Danese S,Peyrin L. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United Eur. Gastroenterol. J. 2021. 9. (4):p. 451-460. IF:6,866. (1).
